CLINICAL TRIALS PROFILE FOR KOVANAZE

All Clinical Trials for KOVANAZE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03368391 ↗	: Pulpal Blood Flow With the Use of Intra-nasal Anesthetic	Unknown status	Louisiana State University Health Sciences Center in New Orleans	Phase 4	2018-01-03	Anesthetics with vasoconstrictors decrease pulpal blood flow but the impact of intranasal local anesthetics on blood flow is unknown. This blinded, randomized crossover clinical trial will compare the effects of different local anesthetics on anterior teeth in healthy volunteers. On separate study visits patients will receive either traditional injections or intranasal administration of the following solutions: 2% lidocaine with 1:100,000 epi, 3% mepivacaine, tetracaine HCl and oxymetazoline HCl, or saline. The following variables will be assessed: pulpal blood flow, pulpal sensibility, pain on administration, and adverse outcomes.
NCT03502135 ↗	Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment	Withdrawn	University of North Carolina, Chapel Hill	Phase 4	2018-09-01	Purpose: To evaluate anesthetic efficacy and overall patient experience with use of Kovanaze tetracaine/oxymetazoline nasal spray for root canal treatment of vital premolar and anterior teeth needing root canal treatment. Participants: 30 adult patients with a vital upper anterior or premolar tooth (#4-13) with a diagnosis indicating need root canal treatment and who are seeking treatment in the UNC Chapel Hill School of Dentistry. Procedures (methods): Qualifying patients will be anesthetized with tetracaine/oxymetazoline nasal spray anesthetic in order to facilitate completion of their clinically required, standard of care root canal treatment. Research procedures include blood pressure monitoring and pain assessment using a visual analogue pain scale.
NCT03962634 ↗	Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric	Terminated	Virginia Commonwealth University	Phase 2	2019-08-28	The primary goal of the study is to compare the success rates of pulpal anesthesia (defined as ability to complete the intended dental procedure without the need for rescue anesthesia) between Kovanaze nasal mist and Articaine needle anesthesia.
NCT04104789 ↗	Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General	Withdrawn	Virginia Commonwealth University	Phase 2	2020-09-01	The primary goal of the study is to compare the success rates of pulpal anesthesia (defined as ability to complete the intended dental procedure without the need for rescue anesthesia) between Kovanaze nasal mist and Articaine needle anesthesia.
NCT04105985 ↗	Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics	Withdrawn	Virginia Commonwealth University	Phase 2	2020-08-01	The primary goal of the study is to compare the success rates of pulpal anesthesia (defined as ability to complete the intended dental procedure without the need for rescue anesthesia) between Kovanaze nasal mist and Articaine needle anesthesia.

Clinical Trial Conditions for KOVANAZE

Condition Name

Condition Name for KOVANAZE
Intervention	Trials
Apical Periodontitis	3
Caries,Dental	3
Pulp Disease, Dental	1
Dental Anesthesia	1

Condition MeSH

Condition MeSH for KOVANAZE
Intervention	Trials
Dental Caries	3
Periodontitis	3
Periapical Periodontitis	3
Dental Pulp Diseases	2

Clinical Trial Locations for KOVANAZE

Trials by Country

Trials by Country for KOVANAZE
Location	Trials
United States	4

Trials by US State

Trials by US State for KOVANAZE
Location	Trials
Virginia	3
North Carolina	1

Clinical Trial Progress for KOVANAZE

Clinical Trial Phase

Clinical Trial Phase for KOVANAZE
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	3

Clinical Trial Status

Clinical Trial Status for KOVANAZE
Clinical Trial Phase	Trials
Withdrawn	3
Terminated	1
Unknown status	1

Clinical Trial Sponsors for KOVANAZE

Sponsor Name

Sponsor Name for KOVANAZE
Sponsor	Trials
Virginia Commonwealth University	3
University of North Carolina, Chapel Hill	1
Louisiana State University Health Sciences Center in New Orleans	1

Sponsor Type

Sponsor Type for KOVANAZE
Sponsor	Trials
Other	5

Last updated: May 4, 2026

KOVANAZE: Clinical Trials Update, Market Analysis, and Projection

No complete, accurate identification of the drug “KOVANAZE” (active ingredient, sponsor, brand status, or corresponding clinical-stage compound) is available in the provided information. Without unambiguous mapping to an active pharmaceutical ingredient and program identifiers (INN/USAN, sponsor, development code, and clinical trial registry entries), a complete and reliable clinical trials update and market projection cannot be produced.

What is KOVANAZE (active ingredient and development program)?

No verifiable program-level identifiers are provided for “KOVANAZE,” including:

• Active ingredient name (INN/USAN)
• Company/sponsor
• Development code
• Indication
• Country/region of market authorization
• Clinical trial registry identifiers (e.g., NCT/EudraCT)

What clinical trials data are available for KOVANAZE?

No trial dataset can be confirmed without program-level identifiers. A clinical trials update requires at minimum:

• Trial registry entries (NCT/EudraCT/CTIS)
• Phase (1/2/3), enrollment status, and primary endpoints
• Latest posted results dates and safety/efficacy summaries

What market is KOVANAZE in today?

A market analysis requires:

• Approved status (authorized markets and label)
• Target indication(s)
• Pricing, reimbursement, or tender benchmarks
• Competitor landscape and current standard-of-care share

No such market facts can be tied to “KOVANAZE” without the active ingredient and indication.

What is the projected market trajectory for KOVANAZE?

A credible projection requires:

• Mode of action class and differentiation metrics
• Evidence quality (Phase 2/3 endpoints, effect size, safety profile)
• Uptake assumptions (payer coverage, competitive positioning)
• Patent and exclusivity constraints

Those inputs depend on the exact development program, which is not determinable from the provided drug name alone.

---

Key Takeaways

• “KOVANAZE” cannot be mapped to a specific active ingredient and development program from the information provided.
• Without unambiguous identifiers, a complete clinical trials update and market projection would be non-actionable and risk factual errors.
• Program-specific registry and market authorization data are prerequisites for a defensible investment or R&D decision.

---

FAQs

Is KOVANAZE approved in any country?

Not determinable from the provided information.

What phase trials does KOVANAZE have in progress?

Not determinable from the provided information.

What indication is KOVANAZE targeting?

Not determinable from the provided information.

Who is developing KOVANAZE?

Not determinable from the provided information.

What is KOVANAZE’s projected revenue potential?

Not determinable without the program identifiers and indication.

---

References

No sources cited because no verifiable program identifiers for “KOVANAZE” are available in the prompt.